Clinical Research

Clinical Research Program

At the CU Hemophilia and Thrombosis Center, research and patient care go hand in hand. Our Clinical Research Program gives patients the chance to try promising new treatments and help improve care for others in the future. We take part in many studies that explore both bleeding and clotting disorders, from testing new therapies to learning how people manage their conditions in everyday life.

We conduct two main types of clinical research at the HTC:

• Industry-Sponsored Trials: These studies are developed with pharmaceutical companies to test new medicines or therapies. Participants may gain early access to treatments not yet widely available, all under close medical supervision. Our center has helped lead breakthrough research which are bringing the goal of a lasting cure closer to reality.

• Investigator-Initiated Studies: These projects are designed and led by our own researchers, often with support from federal or foundation grants. Examples include, developing improved blood tests for diagnosis, understanding how treatment costs and quality of life affect families, finding new ways to improve daily care for people with bleeding and clotting disorders.

Areas of Focus: About two-thirds of our research focuses on bleeding disorders such as hemophilia A and B, von Willebrand disease, and rare factor deficiencies. We make sure to include people with rare conditions so every patient’s experience counts These studies may test new medications, track joint health and pain, or study why some patients develop inhibitors that reduce treatment effectiveness. The other third of our work looks at clotting disorders. Here, we study blood clots (thrombosis) in both children and adults buy examining risk factors, prevention, and recovery after conditions like deep vein thrombosis or stroke.